« Home | Gulf War Illness and the Health of Gulf War Vetera... » | Sickening results » | Costly program with a shady past » | Scientific impossibility: Did FBI get their man in... » | Vaccinations Against Bird Flu Should Happen Now, S... » | Panel OKs Anthrax Shots for First Responders » | PREPA - and what this means to you » | Contact Your Reps: DHHS designates an anthrax emer... » | Emergency declarations smooth way for vaccine make... » | Chertoff Memo: How to Declare an Anthrax Emergency... »

Emergent BioSolutions Receives FDA approval for Supplemental Biologics License Application for BioThrax

Emergent BioSolutions Receives FDA approval for Supplemental Biologics License Application for BioThrax - Quick Facts

http://www.rttnews.com/Content/QuickFacts.aspx?Node=B1&Id=807804%20&Category=Quick%20Facts

Emergent BioSolutions Inc. (EBS: News ) announced that FDA has approved its supplemental Biologics License Application or sBLA for Anthrax Vaccine Adsorbed or BioThrax to prevent disease caused by Bacillus anthracis. The approval for supplement license was based on an interim analysis of data from a large multicenter study initiated in 2002.

The company said the supplement provides for a change in the route of administration and a reduction in the total number of vaccinations. The new schedule for BioThrax is five intramuscular doses at 0, 1, 6, 12 and 18 months, compared with the former schedule of six subcutaneous doses.

Archives